Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES

(GILD)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/22/2020 05/26/2020 05/27/2020 05/28/2020 05/29/2020 Date
73.34(c) 73.18(c) 74.9(c) 75.32(c) 77.83 Last
6 268 461 12 308 074 11 752 331 10 517 501 24 375 126 Volume
-0.19% -0.22% +2.35% +0.56% +3.33% Change
More quotes
Financials (USD)
Sales 2020 22 300 M - -
Net income 2020 3 812 M - -
Net cash position 2020 1 769 M - -
P/E ratio 2020 26,4x
Yield 2020 3,46%
Sales 2021 22 520 M - -
Net income 2021 6 357 M - -
Net cash position 2021 4 595 M - -
P/E ratio 2021 15,3x
Yield 2021 3,60%
Capitalization 94 479 M 94 479 M -
EV / Sales 2020 4,16x
EV / Sales 2021 3,99x
Nbr of Employees 11 800
Free-Float 99,4%
More Financials
Company
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.5%): for the treatment of HIV, hepatitis B virus and hepatitis C virus (93.4% of net sales) and other (6.6%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.5%): especially royalties and... 
More about the company
Surperformance© ratings of Gilead Sciences
Trading Rating : Investor Rating :
More Ratings
Latest news on GILEAD SCIENCES
02:05pGILEAD SCIENCES : Response to U.S. Senators on Trial Diversity
PU
08:02aGILEAD SCIENCES : Yescarta® (Axicabtagene Ciloleucel) Demonstrates High Rates of..
BU
08:02aGILEAD SCIENCES : Investigational Magrolimab in Combination With Azacitidine Dem..
BU
05/28GLOBAL MARKETS LIVE: Turmoil continues for the airline sector
05/28GILEAD SCIENCES : With Great IP Comes Great Responsibility - Developing And Depl..
AQ
05/28Foreign investors turn net buyers of Japan stocks for first time in 15 weeks
RE
05/27Gilead Sciences, Arcus Biosciences Ink 10-Year Partnership
DJ
05/27Merck Does Deals To Develop Vaccines -- WSJ
DJ
05/26Merck Does Deals to Develop Coronavirus Vaccines, Drug -- Update
DJ
05/26Merck to buy Austrian vaccine maker as it jumps into COVID-19 race
RE
05/26GILEAD SCIENCES : Selected NHS patients to access coronavirus treatment remdesiv..
AQ
05/26Merck Does Deals to Develop Coronavirus Vaccines, Drug
DJ
05/26TAKE FIVE : Coronavirus vaccine race is on
RE
05/24GILEAD SCIENCES : The game-changing vaccine concept
AQ
05/23WALL STREET WEEK AHEAD : Investors look beyond drug makers as hunt for COVID-19 ..
RE
More news
News in other languages on GILEAD SCIENCES
02:05pGILEAD SCIENCES : Response to U.S. Senators on Trial Diversity
09:30aZulassung von Remdesivir als Mittel gegen Covid-19 verzögert sich
08:02aGILEAD SCIENCES : Yescarta® (Axicabtagene Ciloleucel) Demonstrates High Rates of..
08:02aGILEAD SCIENCES : Investigational Magrolimab in Combination With Azacitidine Dem..
05/28Bourse Zurich: l'optimisme l'a emporté, le SMI repasse les 9900 points
More news
Stock Trading Strategies
GILEAD SCIENCES - 02/03
Volatility should make a big comeback
BUY
More Stock Trading Analysis
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 80,20 $
Last Close Price 77,83 $
Spread / Highest target 24,6%
Spread / Average Target 3,05%
Spread / Lowest Target -25,5%
EPS Revisions
Managers
NameTitle
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
William A. Lee Executive Vice President-Research
Merdad V. Parsey Chief Medical Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES15.91%94 479
VERTEX PHARMACEUTICALS26.69%71 918
REGENERON PHARMACEUTICALS53.99%64 390
WUXI APPTEC CO., LTD.15.61%32 212
GENMAB A/S39.93%20 070
BEIGENE, LTD.-2.05%12 591